Along with the presence of CD133-positive HCC stem cell-like cells [8], a growing number of studies indicate that CD133 expression is correlated with higher stage tumours and poor prognosis in HCC patients [9, 10], suggesting a promising strategy of using CD133 as a target for HCC treatment. The gene discussed is PROM1; the disease is hepatocellular carcinoma.